Sojournix Stock

sojournixpharma.comHealthcareFounded: 1900Funding to Date: $71.39MM

Sojournix is a clinical stage biopharmaceutical company focused on developing and commercializing novel therapies for the treatment of women’s health and neuroendocrine disorders.

Register for Details

For more details on financing and valuation for Sojournix, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

By registering, you agree to the Forge Terms of Use. Already registered? Click here to log in

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for Sojournix.

Register Today

Team

Management Team

Scott Rakestraw
Board Member & Co-Founder
Daniel Grau
Co-Founder, President, Chief Executive Officer, and Director

Board Members

Martin Freed MD
Peter Kolchinsky
Daniel Grau
Scott Rakestraw
Aaron Davis
Tavistock Group
Peter Lanciano

Other companies like Sojournix in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.6B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$150MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$296.3MM
Sector
Last Round Est. Valuation
$4.8B

News

Sojournix, a developer of new medicines for the treatment of women's health and neuroendocrine disorders, completed a $44m Series C financing